{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'A potential DILI is defined as:', 'ALT or AST elevation > 3 times (3x) upper limit of normal (ULN) and', 'Total bilirubin > 2 X ULN, without initial findings of cholestasis (elevated', 'serum alkaline phosphatase) and', 'No other immediately apparent possible causes of aminotransferase (AT)', 'elevation and hyperbilirubinemia including but not limited to viral hepatitis,', 'pre-existing chronic or acute liver disease or tumor(s), or the administration of', 'other drug(s) known to be hepatotoxic', 'In general, an increase of AT to > 3 X ULN should be followed by repeat testing within 48', '- 72 hours of all four of the usual measures (ALT, AST, alkaline phosphatase, and total', 'bilirubin) to confirm the abnormalities and to determine if they are increasing or', 'decreasing. An inquiry regarding symptoms should also be made (e.g., fatigue, nausea,', 'vomiting, right upper quadrant pain or tenderness, fever, rash). Subjects may be retested', 'locally, but normal laboratory ranges should be recorded and results made available to the', 'Investigator immediately. All data must be recorded in the CRF. If symptoms persist or', 'repeat testing shows AT > 3 X ULN for subjects with normal baseline measures or 2-fold', 'increases above baseline values for subjects with elevated values before drug exposure,', 'close observation should be initiated. If close monitoring is not possible, blinded', 'investigational product should be discontinued.', 'Close observation includes:', 'Repeating liver enzyme and serum bilirubin tests two or three times weekly.', 'Frequency of retesting can decrease to once a week or less if abnormalities', 'stabilize or the trial drug has been discontinued and the subject is', 'asymptomatic.', 'Obtaining a more detailed history of symptoms and prior or concurrent', 'diseases', 'Obtaining a history of concomitant drug use (including nonprescription', 'medications and herbal and dietary supplement preparations), alcohol use,', 'recreational drug use, and special diets', '88']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Ruling out acute viral hepatitis types A, B, C, D, and E; autoimmune or', 'alcoholic hepatitis; non-alcoholic steatohepatitis (NASH); hypoxic/ischemic', 'hepatopathy; and biliary tract disease', 'Obtaining a history of exposure to environmental chemical agents', 'Obtaining additional tests to evaluate liver function, as appropriate', '(e.g., international normalized ratio [INR], direct bilirubin)', 'Considering gastroenterology or hepatology consultations', 'Blinded investigational product will be discontinued if potential DILI is suspected and:', 'ALT or AST > 8 X ULN', 'ALT or AST > 5 X ULN for more than 2 weeks', 'ALT or AST > 3 X ULN and (TBL > 2x ULN or INR > 1.5)', 'ALT or AST > 3 X ULN with the appearance of fatigue, nausea, vomiting,', 'right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia', 'All subjects showing possible DILI should be followed until all abnormalities return to', 'normal or to the baseline state.', 'Any hepatic related adverse event should be recorded and the Hepatic Adverse Event', 'eCRF triggered from the Adverse Event page.', '6.1.8.4', 'Monitoring and Management of Edema', 'The majority of the edema events with rovalpituzumab tesirine have been reported as low', 'grade 1 or 2 (mild or moderate); however, a small number of fatal events of generalized', 'edema have been reported with rovalpituzumab tesirine. Physical exams and monitoring', 'of weight gain and signs or symptoms of fluid retention should be conducted during', 'treatment. Edema events were reported during treatment and may occur up to several', 'months after last Rova-T dose. As a result subjects should be advised of signs and', 'symptoms of fluid retention as well as monitor their weight and contact treating physician', 'if they arise during this time.', '89']\n\n###\n\n", "completion": "END"}